Who are Isatuximab Carfilzomib Lenalidomide Dexamethasone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/isatuximab-carfilzomib-lenalidomide-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Isatuximab Carfilzomib Lenalidomide Dexamethasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isatuximab Carfilzomib Lenalidomide Dexamethasone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: monoclonal antibody + proteasome inhibitor + immunomodulatory agent + corticosteroid. Area:

phase 3 Combination therapy: monoclonal antibody + proteasome inhibitor + immunomodulatory agent + corticosteroid CD38 (isatuximab); proteasome (carfilzomib); cereblon (lenalidomide); glucocorticoid receptor (dexamethasone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Isatuximab Carfilzomib Lenalidomide Dexamethasone (Isatuximab Carfilzomib Lenalidomide Dexamethasone) — European Myeloma Network B.V.. This is a four-drug combination regimen that targets multiple pathways in multiple myeloma: isatuximab blocks CD38 on myeloma cells, carfilzomib inhibits the proteasome, lenalidomide is an immunomodulatory agent, and dexamethasone is a corticosteroid.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Isatuximab Carfilzomib Lenalidomide Dexamethasone TARGET	Isatuximab Carfilzomib Lenalidomide Dexamethasone	European Myeloma Network B.V.	phase 3	Combination therapy: monoclonal antibody + proteasome inhibitor + immunomodulatory agent + corticosteroid	CD38 (isatuximab); proteasome (carfilzomib); cereblon (lenalidomide); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: monoclonal antibody + proteasome inhibitor + immunomodulatory agent + corticosteroid class)

European Myeloma Network B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Isatuximab Carfilzomib Lenalidomide Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/isatuximab-carfilzomib-lenalidomide-dexamethasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab